Complement Therapeutics

  • John D. Lambris
  • V. Michael Holers
  • Daniel Ricklin

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 735)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Daniel Ricklin, John D. Lambris
    Pages 1-22
  3. Péter Gál, József Dobó, László Beinrohr, Gábor Pál, Péter Závodszky
    Pages 23-40
  4. Hideharu Sekine, Minoru Takahashi, Daisuke Iwaki, Teizo Fujita
    Pages 41-53
  5. Berhane Ghebrehiwet, Jolyon Jesty, Rama Vinayagasundaram, Uma Vinayagasundaram, Yan Ji, Alisa Valentino et al.
    Pages 97-110
  6. Hiroshi Nishiura
    Pages 111-121
  7. Constantinos Deltas, Daniel Gale, Terence Cook, Konstantinos Voskarides, Yiannis Athanasiou, Alkis Pierides
    Pages 189-196
  8. George Hajishengallis, John D. Lambris
    Pages 197-206
  9. Mariusz Z. Ratajczak, ChiHwa Kim, Janina Ratajczak, Anna Janowska-Wieczorek
    Pages 219-232
  10. Mohammad A. Khan, Mark R. Nicolls
    Pages 233-246
  11. Steven Sacks, Julia Karegli, Conrad A. Farrar, Elham Asgari, Wilhelm Schwaeble, Wuding Zhou et al.
    Pages 247-255
  12. Kristina N. Ekdahl, Jaan Hong, Osama A. Hamad, Rolf Larsson, Bo Nilsson
    Pages 257-270
  13. Joshua M. Thurman, Bärbel Rohrer
    Pages 271-282

About this book

Introduction

This book highlights progress and trends in the rapidly evolving field of complement-related drug discovery and spotlights examples of clinical applications. As an integral part of innate immunity and critical mediator in homeostatic and inflammatory processes, the human complement system has been identified as contributor to a large number of disorders including ocular, cardiovascular, metabolic, autoimmune, and inflammatory diseases as well as in ischemia/reperfusion injury, cancer and sepsis. In addition, complement is often involved in adverse immune reactions to biomaterials, cell and organ transplants or drug delivery systems. Although the complement cascade with its close to 50 extracellular protein targets has long been recognized as an attractive system for therapeutic modulation, the past few years have seen a particularly strong boost in interest. Fueled by novel research insight and the marketing of the first complement-targeted drugs, a plethora of highly creative treatment approaches and potent drug candidates have recently emerged and are currently evaluated in disease models and clinical trials.

 

The chapters in this book cover a wide range of topics related to the development of complement therapeutics, ranging from the molecular and functional description of complement targets to the presentation of novel inhibitors, improved treatment strategies as well as examples of disease models and clinical applications. The broad and up-to-date overview on a highly versatile and dynamic field renders this book an indispensable source of information for researchers and clinicians dealing with therapeutic and disease-related aspects of the human complement system.

Editors and affiliations

  • John D. Lambris
    • 1
  • V. Michael Holers
    • 2
  • Daniel Ricklin
    • 3
  1. 1.MedicineUniversity Of Pennsylvania Department Of Pathology Laboratory OfPhiladelphiaUSA
  2. 2.University of Colorado School of MedicinAuroraUSA
  3. 3.Department of Pathology & Laboratory MedUniversity of Pennsylvania School of MedPhiladelphiaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4614-4118-2
  • Copyright Information Springer Science+Business Media New York 2013
  • Publisher Name Springer, Boston, MA
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-1-4614-4117-5
  • Online ISBN 978-1-4614-4118-2
  • Series Print ISSN 0065-2598
  • Series Online ISSN 2214-8019
  • About this book